Beijing Science Sun Pharmaceutical Co Ltd (300485) - Total Assets
Based on the latest financial reports, Beijing Science Sun Pharmaceutical Co Ltd (300485) holds total assets worth CN¥3.60 Billion CNY (≈ $527.49 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Beijing Science Sun Pharmaceutical Co Lt to assess how comfortably operating cash covers total debt obligations.
Beijing Science Sun Pharmaceutical Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Beijing Science Sun Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Beijing Science Sun Pharmaceutical Co Lt shareholders equity for net asset value and shareholders' equity analysis.
Beijing Science Sun Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Science Sun Pharmaceutical Co Ltd's total assets of CN¥3.60 Billion consist of 48.2% current assets and 51.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 2.1% |
| Accounts Receivable | CN¥52.19 Million | 1.5% |
| Inventory | CN¥81.37 Million | 2.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥339.83 Million | 9.6% |
| Goodwill | CN¥21.87 Million | 0.6% |
Asset Composition Trend (2011–2024)
This chart illustrates how Beijing Science Sun Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing Science Sun Pharmaceutical Co Lt (300485) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Science Sun Pharmaceutical Co Ltd's current assets represent 48.2% of total assets in 2024, a decrease from 64.0% in 2011.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2024, down from 45.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 5.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 9.6% of total assets.
Beijing Science Sun Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Beijing Science Sun Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Beijing Science Sun Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 21.80 | 20.33 | 10.93 |
| Quick Ratio | 20.91 | 19.24 | 9.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.70 Billion | CN¥1.61 Billion | CN¥1.35 Billion |
Beijing Science Sun Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Science Sun Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.59 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -1.9% |
| Total Assets | CN¥3.55 Billion |
| Market Capitalization | $644.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Science Sun Pharmaceutical Co Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Beijing Science Sun Pharmaceutical Co Ltd's assets decreased by 1.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Beijing Science Sun Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total assets of Beijing Science Sun Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.55 Billion ≈ $519.75 Million |
-1.94% |
| 2023-12-31 | CN¥3.62 Billion ≈ $530.04 Million |
+1.49% |
| 2022-12-31 | CN¥3.57 Billion ≈ $522.27 Million |
+4.92% |
| 2021-12-31 | CN¥3.40 Billion ≈ $497.77 Million |
+13.73% |
| 2020-12-31 | CN¥2.99 Billion ≈ $437.69 Million |
+6.61% |
| 2019-12-31 | CN¥2.81 Billion ≈ $410.53 Million |
+1.63% |
| 2018-12-31 | CN¥2.76 Billion ≈ $403.96 Million |
+12.52% |
| 2017-12-31 | CN¥2.45 Billion ≈ $359.01 Million |
+10.68% |
| 2016-12-31 | CN¥2.22 Billion ≈ $324.36 Million |
+13.97% |
| 2015-12-31 | CN¥1.94 Billion ≈ $284.59 Million |
+170.73% |
| 2014-12-31 | CN¥718.35 Million ≈ $105.12 Million |
+32.77% |
| 2013-12-31 | CN¥541.04 Million ≈ $79.17 Million |
+36.93% |
| 2012-12-31 | CN¥395.13 Million ≈ $57.82 Million |
+41.24% |
| 2011-12-31 | CN¥279.77 Million ≈ $40.94 Million |
-- |
About Beijing Science Sun Pharmaceutical Co Ltd
Beijing Science Sun Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of injections in China. The company offers products for cardiovascular, cerebrovascular, immunomodulation, and nervous systems, among others. It is also involved in the research, development, production, and sale of raw materials; the extraction of traditional Chin… Read more